Last Updated: November 17, 2026

Claims for Patent: 11,896,717

« Back to Dashboard


Summary for Patent: 11,896,717
Title:Sustained-release dosage forms of ruxolitinib
Abstract:The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Inventor(s):Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
Assignee: Incyte Corp , Incyte Holdings Corp
Application Number:US18/090,547
Patent Claims: 1. An oral sustained release dosage form comprising: ruxolitinib phosphate, and a means for sustained release of the ruxolitinib phosphate, wherein the ruxolitinib phosphate is present in the dosage form in an amount ranging from 10 mg to 60 mg on a free base basis, wherein the dosage form is suitable for oral administration, wherein the administration of the dosage form results in a ratio of mean peak to plasma concentration (Cmax) to mean 12-hour plasma concentration (C12h) of ruxolitinib of 10 or less, and wherein the administration of the dosage form to a human results in a mean half-life (t1/2) of from 3.5 hours to 11 hours.

2. The oral sustained release dosage form of claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 10 mg on a free base basis.

3. The oral sustained release dosage form of claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 12.5 mg on a free base basis.

4. The oral sustained release dosage form of claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 20 mg on a free base basis.

5. The oral sustained release dosage form of claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 25 mg on a free base basis.

6. The oral sustained release dosage form of claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 30 mg on a free base basis.

7. The oral sustained release dosage form of claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 37.5 mg on a free base basis.

8. The oral sustained release dosage form of claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 40 mg on a free base basis.

9. The oral sustained release dosage form of claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 50 mg on a free base basis.

10. The oral sustained release dosage form of claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 60 mg on a free base basis.

11. The oral sustained-release dosage form of claim 1, wherein administration of the dosage form to a human results in a ratio of mean peak plasma concentration (Cmax) to mean 12-hour plasma concentration (C12h) of ruxolitinib of 1 to 10.

12. The oral sustained-release dosage form of claim 1, wherein administration of the dosage form to a human results in a ratio of mean peak plasma concentration (Cmax) to mean 12-hour plasma concentration (C12h) of ruxolitinib of 2 to 7.

13. The oral sustained-release dosage form of claim 1, wherein administration of the dosage form to a human results in a mean half-life (t1/2) of from 4 hours to 8 hours.

14. The oral sustained-release dosage form of claim 1, wherein the sustained-release dosage form has a mean relative bioavailability based on AUC of from 65% to 110% relative to an immediate release formulation comprising the same amount of ruxolitinib phosphate in humans.

15. The oral sustained-release dosage form of claim 1, wherein the dosage form is a tablet.

16. The oral sustained-release dosage form of claim 1, wherein the dosage form is a capsule.

17. The oral sustained-release dosage form of claim 1, wherein administration of the dosage form to a human results in a mean time to peak plasma concentration (tmax) of ruxolitinib of 1.5 hours to 5 hours.

18. A method of treating a disease selected from myelofibrosis, polycythemia vera, and graft versus host disease in a human patient in need thereof, comprising administering to the patient the oral sustained-release dosage form of claim 1 once per day.

19. The method of claim 18, wherein the disease is myelofibrosis.

20. The method of claim 19, wherein the myelofibrosis is primary myelofibrosis (PMF), postpolycythemia vera myelofibrosis (PV-MF), or post-essential thrombocythemia myelofibrosis (post ET-MF).

21. The method of claim 18, wherein the disease is polycythemia vera.

22. The method of claim 18, wherein the disease is graft versus host disease.

23. The method of claim 18, wherein administration of the dosage form to a human patient results in a reduction in thrombocytopenia or anemia relative to an immediate-release dosing regimen.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.